Merck and Schering-Plough Settle Lawsuits Over Vytorin and Zetia Cholesterol Pills
This article was originally published in The Pink Sheet Daily
Executive Summary
This marks the second time in recent weeks that the drug makers have settled large-scale litigation related to the medicines.
You may also be interested in...
Merck Clinical Trial Compliance Settlement Relies On Board Oversight
For a three-year period Merck will inform a committee of its board if trial results are not reported within 12 months; the agreement resolves a shareholder derivative suit claiming Schering directors caused results of the Vytorin ENHANCE trial to be suppressed.
No Surprises From ENHANCE At ACC Mean Vytorin Hopes Hang On IMPROVE-IT
CHICAGO - With the full presentation of the results of the failed ENHANCE study at the American College of Cardiology annual meeting, a ringing endorsement for statin use and the results of IMPROVE-IT four years away, the door seems almost closed on Merck/Schering-Plough's Zetia (ezetimibe) and Vytorin (ezetimibe/simvastatin)
The John Green Effect: Will Industry Be Influenced Again?
Drug and device makers regularly use media to sway consumers. But some advocacy groups recently turned the tables by using social media to sway industry.